Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Increased Immunosuppression Is Related to Increased Amounts of Ascites and Inferior Prognosis in Ovarian Cancer.

Coosemans AN, Baert T, D'Heygere V, Wouters R, DE Laet L, VAN Hoylandt A, Thirion G, Ceusters J, Laenen A, Vandecaveye V, Vergote I.

Anticancer Res. 2019 Nov;39(11):5953-5962. doi: 10.21873/anticanres.13800.

PMID:
31704820
2.

Myeloid-derived suppressor cells at diagnosis may discriminate between benign and malignant ovarian tumors.

Coosemans A, Baert T, Ceusters J, Busschaert P, Landolfo C, Verschuere T, Van Rompuy AS, Vanderstichele A, Froyman W, Neven P, Van Calster B, Vergote I, Timmerman D.

Int J Gynecol Cancer. 2019 Nov;29(9):1381-1388. doi: 10.1136/ijgc-2019-000521.

PMID:
31685557
3.

Trial watch: dendritic cell vaccination for cancer immunotherapy.

Sprooten J, Ceusters J, Coosemans A, Agostinis P, De Vleeschouwer S, Zitvogel L, Kroemer G, Galluzzi L, Garg AD.

Oncoimmunology. 2019 Jul 18;8(11):e1638212. doi: 10.1080/2162402X.2019.1638212. eCollection 2019. Review.

PMID:
31646087
4.

CT-2A neurospheres-derived high-grade glioma in mice: a new model to address tumor stem cells and immunosuppression.

Riva M, Wouters R, Weerasekera A, Belderbos S, Nittner D, Thal DR, Baert T, Giovannoni R, Gsell W, Himmelreich U, Van Ranst M, Coosemans A.

Biol Open. 2019 Sep 12;8(9). pii: bio044552. doi: 10.1242/bio.044552.

5.

Circulating Protein Biomarkers to Differentiate Uterine Sarcomas from Leiomyomas.

Glorie N, Baert T, VAN DEN Bosch T, Coosemans AN.

Anticancer Res. 2019 Aug;39(8):3981-3989. doi: 10.21873/anticanres.13553. Review.

PMID:
31366479
6.

Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer.

Baert T, Vankerckhoven A, Riva M, Van Hoylandt A, Thirion G, Holger G, Mathivet T, Vergote I, Coosemans A.

Front Immunol. 2019 Jun 4;10:1273. doi: 10.3389/fimmu.2019.01273. eCollection 2019.

7.

Combining conventional therapy with immunotherapy: A risky business?

Coosemans A, Vankerckhoven A, Baert T, Boon L, Ruts H, Riva M, Blagden S, Delforge M, Concin N, Mirza MR, Ledermann JA, du Bois A, Vergote I.

Eur J Cancer. 2019 May;113:41-44. doi: 10.1016/j.ejca.2019.02.014. Epub 2019 Apr 6.

PMID:
30965214
8.

Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study.

Froyman W, Landolfo C, De Cock B, Wynants L, Sladkevicius P, Testa AC, Van Holsbeke C, Domali E, Fruscio R, Epstein E, Dos Santos Bernardo MJ, Franchi D, Kudla MJ, Chiappa V, Alcazar JL, Leone FPG, Buonomo F, Hochberg L, Coccia ME, Guerriero S, Deo N, Jokubkiene L, Kaijser J, Coosemans A, Vergote I, Verbakel JY, Bourne T, Van Calster B, Valentin L, Timmerman D.

Lancet Oncol. 2019 Mar;20(3):448-458. doi: 10.1016/S1470-2045(18)30837-4. Epub 2019 Feb 5.

9.

Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients.

Baert T, Van Camp J, Vanbrabant L, Busschaert P, Laenen A, Han S, Van Nieuwenhuysen E, Vergote I, Coosemans A.

Gynecol Oncol. 2018 Jul;150(1):31-37. doi: 10.1016/j.ygyno.2018.05.004. Epub 2018 May 9.

PMID:
29751991
10.

Differences in ultrasound features of papillations in unilocular-solid adnexal cysts: a retrospective international multicenter study.

Landolfo C, Valentin L, Franchi D, Van Holsbeke C, Fruscio R, Froyman W, Sladkevicius P, Kaijser J, Ameye L, Bourne T, Savelli L, Coosemans A, Testa A, Timmerman D.

Ultrasound Obstet Gynecol. 2018 Aug;52(2):269-278. doi: 10.1002/uog.18951.

11.

Orientation of Preclinical Research in Ovarian Cancer.

Baert T, Garg AD, Agostinis P, Vergote I, Coosemans A.

Int J Gynecol Cancer. 2017 Oct;27(8):1579-1586. doi: 10.1097/IGC.0000000000001053. Review.

PMID:
28945211
12.

Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative.

Cuppens T, Annibali D, Coosemans A, Trovik J, Ter Haar N, Colas E, Garcia-Jimenez A, Van de Vijver K, Kruitwagen RP, Brinkhuis M, Zikan M, Dundr P, Huvila J, Carpén O, Haybaeck J, Moinfar F, Salvesen HB, Stukan M, Mestdagh C, Zweemer RP, Massuger LF, Mallmann MR, Wardelmann E, Mints M, Verbist G, Thomas D, Gommé E, Hermans E, Moerman P, Bosse T, Amant F.

Clin Cancer Res. 2017 Mar 1;23(5):1274-1285. doi: 10.1158/1078-0432.CCR-16-2149.

13.

Ovarian cancer and the immune system.

Baert T, Vergote I, Coosemans A.

Gynecol Oncol Rep. 2017 Jan 6;19:57-58. doi: 10.1016/j.gore.2017.01.002. eCollection 2017 Feb.

14.

Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses.

Vanderstichele A, Busschaert P, Smeets D, Landolfo C, Van Nieuwenhuysen E, Leunen K, Neven P, Amant F, Mahner S, Braicu EI, Zeilinger R, Coosemans A, Timmerman D, Lambrechts D, Vergote I.

Clin Cancer Res. 2017 May 1;23(9):2223-2231. doi: 10.1158/1078-0432.CCR-16-1078. Epub 2016 Nov 14.

15.

In Vitro Generation of Murine Dendritic Cells for Cancer Immunotherapy: An Optimized Protocol.

Baert T, Garg AD, Vindevogel E, VAN Hoylandt A, Verbist G, Agostinis P, Vergote I, Coosemans AN.

Anticancer Res. 2016 Nov;36(11):5793-5801.

PMID:
27793901
16.

The Use of Toll-like Receptor 4 Agonist to Reshape the Immune Signature in Ovarian Cancer.

Vindevogel E, Baert T, VAN Hoylandt A, Verbist G, Vande Velde G, Garg AD, Agostinis P, Vergote I, Coosemans AN.

Anticancer Res. 2016 Nov;36(11):5781-5792.

PMID:
27793900
17.

Age-related differences in the sonographic characteristics of endometriomas.

Guerriero S, Van Calster B, Somigliana E, Ajossa S, Froyman W, De Cock B, Coosemans A, Fischerová D, Van Holsbeke C, Alcazar JL, Testa AC, Valentin L, Bourne T, Timmerman D.

Hum Reprod. 2016 Aug;31(8):1723-31. doi: 10.1093/humrep/dew113. Epub 2016 Jun 9.

PMID:
27282774
18.

mRNA Electroporation of Dendritic Cells with WT1, Survivin, and TriMix (a Mixture of caTLR4, CD40L, and CD70).

Coosemans A, Tuyaerts S, Morias K, Corthals J, Heirman C, Thielemans K, Van Gool SW, Vergote I, Amant F.

Methods Mol Biol. 2016;1428:277-83. doi: 10.1007/978-1-4939-3625-0_18.

PMID:
27236806
19.

Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course.

Coosemans A, Decoene J, Baert T, Laenen A, Kasran A, Verschuere T, Seys S, Vergote I.

Oncoimmunology. 2015 Dec 21;5(4):e1111505. eCollection 2016 Apr.

20.

Ovarian cancer in children and adolescents: A rare disease that needs more attention.

Baert T, Storme N, Van Nieuwenhuysen E, Uyttebroeck A, Van Damme N, Vergote I, Coosemans A.

Maturitas. 2016 Jun;88:3-8. doi: 10.1016/j.maturitas.2016.03.003. Epub 2016 Mar 8. Review.

PMID:
27105689
21.

Morcellation and risk of malignancy in presumed ovarian fibromas/fibrothecomas.

Froyman W, Landolfo C, Amant F, Van den Bosch T, Vergote I, Coosemans A, Testa A, Valentin L, Bourne T, Van Calster B, Timmerman D.

Lancet Oncol. 2016 Mar;17(3):273-4. doi: 10.1016/S1470-2045(16)00022-X. Epub 2016 Mar 2. No abstract available.

PMID:
26972853
22.

The dark side of ID8-Luc2: pitfalls for luciferase tagged murine models for ovarian cancer.

Baert T, Verschuere T, Van Hoylandt A, Gijsbers R, Vergote I, Coosemans A.

J Immunother Cancer. 2015 Dec 15;3:57. doi: 10.1186/s40425-015-0102-0. eCollection 2015.

23.

Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death.

Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, Breckpot K, Brough D, Chaurio R, Cirone M, Coosemans A, Coulie PG, De Ruysscher D, Dini L, de Witte P, Dudek-Peric AM, Faggioni A, Fucikova J, Gaipl US, Golab J, Gougeon ML, Hamblin MR, Hemminki A, Herrmann M, Hodge JW, Kepp O, Kroemer G, Krysko DV, Land WG, Madeo F, Manfredi AA, Mattarollo SR, Maueroder C, Merendino N, Multhoff G, Pabst T, Ricci JE, Riganti C, Romano E, Rufo N, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Vacchelli E, Vandenabeele P, Vandenberk L, Van den Eynde BJ, Van Gool S, Velotti F, Zitvogel L, Agostinis P.

Front Immunol. 2015 Nov 20;6:588. doi: 10.3389/fimmu.2015.00588. eCollection 2015.

24.

A view on dendritic cell immunotherapy in ovarian cancer: how far have we come?

Coosemans A, Baert T, Vergote I.

Facts Views Vis Obgyn. 2015;7(1):73-8.

25.

Immunological parameters as a new lead in the diagnosis of ovarian cancer.

Baert T, Timmerman D, Vergote I, Coosemans A.

Facts Views Vis Obgyn. 2015;7(1):67-72.

26.

Dendritic cell immunotherapy in uterine cancer.

Coosemans A, Tuyaerts S, Vanderstraeten A, Vergote I, Amant F, Van Gool SW.

Hum Vaccin Immunother. 2014;10(7):1822-7. doi: 10.4161/hv.28716.

27.

Wilms' tumor gene 1 immunotherapy in pelvic gynecological malignancies.

Coosemans A, Vergote I, Van Gool SW.

Expert Rev Clin Immunol. 2014 Jun;10(6):705-11. doi: 10.1586/1744666X.2014.910119. Epub 2014 May 2. Review.

PMID:
24784346
28.

Dendritic cell-based immunotherapy in ovarian cancer.

Coosemans A, Vergote I, Van Gool SW.

Oncoimmunology. 2013 Dec 1;2(12):e27059. Epub 2013 Nov 6.

29.

Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial.

Coosemans A, Vanderstraeten A, Tuyaerts S, Verschuere T, Moerman P, Berneman ZN, Vergote I, Amant F, VAN Gool SW.

Anticancer Res. 2013 Dec;33(12):5495-500.

PMID:
24324087
30.

Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma.

Coosemans A, Vanderstraeten A, Tuyaerts S, Verschuere T, Moerman P, Berneman Z, Vergote I, Amant F, Van Gool SW.

Anticancer Res. 2013 Sep;33(9):3855-9.

PMID:
24023319
31.

Polymorphisms in inflammation pathway genes and endometrial cancer risk.

Delahanty RJ, Xiang YB, Spurdle A, Beeghly-Fadiel A, Long J, Thompson D, Tomlinson I, Yu H, Lambrechts D, Dörk T, Goodman MT, Zheng Y, Salvesen HB, Bao PP, Amant F, Beckmann MW, Coenegrachts L, Coosemans A, Dubrowinskaja N, Dunning A, Runnebaum IB, Easton D, Ekici AB, Fasching PA, Halle MK, Hein A, Howarth K, Gorman M, Kaydarova D, Krakstad C, Lose F, Lu L, Lurie G, O'Mara T, Matsuno RK, Pharoah P, Risch H, Corssen M, Trovik J, Turmanov N, Wen W, Lu W, Cai Q, Zheng W, Shu XO.

Cancer Epidemiol Biomarkers Prev. 2013 Feb;22(2):216-23. doi: 10.1158/1055-9965.EPI-12-0903. Epub 2012 Dec 5.

32.

Genome-wide association study identifies a possible susceptibility locus for endometrial cancer.

Long J, Zheng W, Xiang YB, Lose F, Thompson D, Tomlinson I, Yu H, Wentzensen N, Lambrechts D, Dörk T, Dubrowinskaja N, Goodman MT, Salvesen HB, Fasching PA, Scott RJ, Delahanty R, Zheng Y, O'Mara T, Healey CS, Hodgson S, Risch H, Yang HP, Amant F, Turmanov N, Schwake A, Lurie G, Trovik J, Beckmann MW, Ashton K, Ji BT, Bao PP, Howarth K, Lu L, Lissowska J, Coenegrachts L, Kaidarova D, Dürst M, Thompson PJ, Krakstad C, Ekici AB, Otton G, Shi J, Zhang B, Gorman M, Brinton L, Coosemans A, Matsuno RK, Halle MK, Hein A, Proietto A, Cai H, Lu W, Dunning A, Easton D, Gao YT, Cai Q, Spurdle AB, Shu XO.

Cancer Epidemiol Biomarkers Prev. 2012 Jun;21(6):980-7. doi: 10.1158/1055-9965.EPI-11-1160. Epub 2012 Mar 16.

33.

Screening for uterine tumours.

Van den Bosch T, Coosemans A, Morina M, Timmerman D, Amant F.

Best Pract Res Clin Obstet Gynaecol. 2012 Apr;26(2):257-66. doi: 10.1016/j.bpobgyn.2011.08.002. Epub 2011 Nov 9. Review.

PMID:
22078749
34.

Wilms tumor gene 1 (WT1) is a prognostic marker in high-grade uterine sarcoma.

Coosemans A, Van Calster B, Verbist G, Moerman P, Vergote I, Van Gool SW, Amant F.

Int J Gynecol Cancer. 2011 Feb;21(2):302-8. doi: 10.1097/IGC.0b013e318207cab5.

PMID:
21734473
35.

Wilms' Tumour gene 1 (WT1) as an immunotherapeutic target.

Coosemans A.

Facts Views Vis Obgyn. 2011;3(2):89-99.

36.

Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma.

Coosemans A, Wölfl M, Berneman ZN, Van Tendeloo V, Vergote I, Amant F, Van Gool SW.

Anticancer Res. 2010 Sep;30(9):3709-14.

PMID:
20944158
37.

Clinical management of uterine sarcomas.

Amant F, Coosemans A, Debiec-Rychter M, Timmerman D, Vergote I.

Lancet Oncol. 2009 Dec;10(12):1188-98. doi: 10.1016/S1470-2045(09)70226-8. Review.

PMID:
19959075
38.

Clinical outcome of ET-743 (Trabectedin; Yondelis) in high-grade uterine sarcomas: report on five patients and a review of the literature.

Amant F, Coosemans A, Renard V, Everaert E, Vergote I.

Int J Gynecol Cancer. 2009 Feb;19(2):245-8. doi: 10.1111/IGC.0b013e31819c0f59. Review.

PMID:
19396002
39.

Wilms' tumour gene 1 (WT1) positivity in endothelial cells surrounding epithelial uterine tumours.

Coosemans A, Van Hove T, Verbist G, Moons L, Neven P, Moerman P, Vergote I, Van Gool SW, Amant F.

Histopathology. 2009 Feb;54(3):384-7. doi: 10.1111/j.1365-2559.2008.03213.x. No abstract available.

PMID:
19236519
40.

Wilms' tumor gene 1 (WT1) in endometrial carcinoma.

Coosemans A, Moerman P, Verbist G, Maes W, Neven P, Vergote I, Van Gool SW, Amant F.

Gynecol Oncol. 2008 Dec;111(3):502-8. doi: 10.1016/j.ygyno.2008.08.032. Epub 2008 Oct 16.

PMID:
18929401
41.

Wilms' tumor gene 1 (WT1) overexpression in neurons in deep endometriosis: a pilot study.

Coosemans A, Moerman P, Vergote I, Koninckx PR, Van Gool SW, Amant F.

Fertil Steril. 2009 Apr;91(4 Suppl):1441-4. doi: 10.1016/j.fertnstert.2008.06.042. Epub 2008 Aug 22.

PMID:
18722603
42.

Upregulation of Wilms' tumour gene 1 (WT1) in uterine sarcomas.

Coosemans A, Nik SA, Caluwaerts S, Lambin S, Verbist G, Van Bree R, Schelfhout V, de Jonge E, Dalle I, Jacomen G, Cassiman JJ, Moerman P, Vergote I, Amant F.

Eur J Cancer. 2007 Jul;43(10):1630-7. Epub 2007 May 24.

PMID:
17531467

Supplemental Content

Loading ...
Support Center